RWA Wealth Partners LLC Grows Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

RWA Wealth Partners LLC increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 6,903 shares of the medical research company’s stock after acquiring an additional 233 shares during the quarter. RWA Wealth Partners LLC’s holdings in Thermo Fisher Scientific were worth $3,591,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in TMO. Schroder Investment Management Group increased its position in Thermo Fisher Scientific by 4.3% in the fourth quarter. Schroder Investment Management Group now owns 1,678,980 shares of the medical research company’s stock worth $873,456,000 after buying an additional 69,885 shares during the period. Arrowstreet Capital Limited Partnership grew its holdings in shares of Thermo Fisher Scientific by 79.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 369,285 shares of the medical research company’s stock worth $192,113,000 after acquiring an additional 162,962 shares during the last quarter. American Money Management LLC lifted its position in shares of Thermo Fisher Scientific by 0.4% in the 4th quarter. American Money Management LLC now owns 5,386 shares of the medical research company’s stock valued at $2,802,000 after acquiring an additional 24 shares in the last quarter. Allianz SE purchased a new stake in Thermo Fisher Scientific in the 4th quarter worth about $7,814,000. Finally, Allstate Corp lifted its position in shares of Thermo Fisher Scientific by 3,264.2% in the fourth quarter. Allstate Corp now owns 11,371 shares of the medical research company’s stock worth $5,916,000 after purchasing an additional 11,033 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on TMO shares. Wells Fargo & Company raised their price objective on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a research report on Friday, January 31st. Citigroup decreased their price target on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Scotiabank lifted their price target on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a “sector perform” rating in a research note on Monday, February 3rd. UBS Group increased their target price on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a report on Friday, January 31st. Finally, Bank of America dropped their price objective on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a report on Friday, December 13th. Four equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $653.23.

Insiders Place Their Bets

In related news, CFO Stephen Williamson sold 9,825 shares of the company’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. This represents a 26.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the transaction, the senior vice president now directly owns 10,816 shares in the company, valued at approximately $5,759,736.32. This trade represents a 25.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 23,900 shares of company stock worth $13,106,062. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Trading Down 2.3 %

Shares of TMO stock opened at $499.75 on Monday. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The stock has a market cap of $188.53 billion, a P/E ratio of 30.23, a price-to-earnings-growth ratio of 2.99 and a beta of 0.79. The stock has a 50 day simple moving average of $541.60 and a 200 day simple moving average of $551.84. Thermo Fisher Scientific Inc. has a 1 year low of $493.30 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.34%. The ex-dividend date is Friday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s dividend payout ratio is currently 10.41%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.